As of June 18, 2026, LENZ Therapeutics's top three insider holders are Biocapital, L.P. Samsara (TenPercentOwner, 8.46Mn shares), Biocapital, L.P. Samsara (TenPercentOwner, 8.03Mn shares), Capital Management, L.P. Ra (Director, 4.01Mn shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| James W Mccollum | - | 0 | 525,565 | 14 May, 2024 |
| Capital Management, L.P. Ra | - | 0 | 4,014,094 | 25 Mar, 2024 |
| Phil Gutry | Chief Business Officer | 299,941 | 0 | 13 Apr, 2022 |
| Venture Capital Vi, L.P. Versant | - | 1,050,599 | 764,127 | 02 Oct, 2025 |
| Biocapital, L.P. Samsara | - | 0 | 8,459,314 | 13 Apr, 2022 |
| Daniel R. Chevallard | Chief Financial Officer | 12,886 | 0 | 30 Mar, 2026 |
| Evert B. Schimmelpennink | President, Ceo And Secretary | 77,289 | 0 | 30 Mar, 2026 |
| Davis Jerel | - | 0 | 1,707,719 | 01 Jul, 2021 |
| Jeffrey P. George | - | 5,592 | 0 | 30 Mar, 2026 |
| Shawn Olsson | Chief Commercial Officer | 4,733 | 0 | 19 Nov, 2025 |
| Marc Odrich | Chief Medical Officer | 99,599 | 0 | 25 Mar, 2024 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 27 Mar, 2026 | Daniel R. Chevallard | Common Stock | A | 7,500 | $8.57 | 12,886 | D | P |
| 27 Mar, 2026 | Evert B. Schimmelpennink | Common Stock | A | 28,089 | $8.95 | 77,289 | D | P |
| 27 Mar, 2026 | Jeffrey P. George | Common Stock | A | 5,592 | $8.92 | 5,592 | D | P |
| 02 Jan, 2026 | Shawn Olsson | Stock Option (right to buy) | A | 84,200 | $0.00 | 84,200 | D | A |
| 02 Jan, 2026 | Evert B. Schimmelpennink | Stock Option (right to buy) | A | 358,100 | $0.00 | 358,100 | D | A |
| 02 Jan, 2026 | Shawn Olsson | Stock Option (right to buy) | A | 84,200 | $0.00 | 84,200 | D | A |
| 02 Jan, 2026 | Daniel R. Chevallard | Stock Option (right to buy) | A | 84,200 | $0.00 | 84,200 | D | A |
| 02 Jan, 2026 | Marc Odrich | Stock Option (right to buy) | A | 84,200 | $0.00 | 84,200 | D | A |
| 02 Jan, 2026 | Marc Odrich | Stock Option (right to buy) | A | 84,200 | $0.00 | 84,200 | D | A |
| 02 Jan, 2026 | Marc Odrich | Restricted Stock Unit | A | 14,000 | $0.00 | 14,000 | D | A |
| 02 Jan, 2026 | Daniel R. Chevallard | Restricted Stock Unit | A | 14,000 | $0.00 | 14,000 | D | A |
| 02 Jan, 2026 | Marc Odrich | Restricted Stock Unit | A | 14,000 | $0.00 | 14,000 | D | A |
| 02 Jan, 2026 | Shawn Olsson | Restricted Stock Unit | A | 14,000 | $0.00 | 14,000 | D | A |
| 02 Jan, 2026 | Shawn Olsson | Restricted Stock Unit | A | 14,000 | $0.00 | 14,000 | D | A |
| 17 Nov, 2025 | Shawn Olsson | Common Stock | A | 10,000 | $2.08 | 14,733 | D | M |
| 17 Nov, 2025 | Shawn Olsson | Common Stock | A | 10,000 | $2.08 | 14,733 | D | M |
| 17 Nov, 2025 | Shawn Olsson | Common Stock | D | 4,212 | $25.74 | 10,521 | D | S |
| 17 Nov, 2025 | Shawn Olsson | Common Stock | D | 4,212 | $25.74 | 10,521 | D | S |
| 17 Nov, 2025 | Shawn Olsson | Common Stock | D | 5,788 | $26.37 | 4,733 | D | S |
| 17 Nov, 2025 | Shawn Olsson | Common Stock | D | 5,788 | $26.37 | 4,733 | D | S |